Search Results - "NIESVIZKY, Ruben"

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation by PALUMBO, Antonio, VINCENT RAJKUMAR, S, DIMOPOULOS, Meletios A, RICHARDSON, Paul G, CAVO, Michele, SPENCER, Andrew, KEITH STEWART, A, SHIMIZU, Kazuyuki, LONIAL, Sagar, SONNEVELD, Pieter, DURIE, Brian G. M, MOREAU, Philippe, SAN MIGUEL, Jesus F, ORLOWSKI, Robert Z, LAROCCA, Alessandra, NIESVIZKY, Ruben, MORGAN, Gareth, LANDGREN, Ola, HAJEK, Roman, EINSELE, Hermann, ANDERSON, Kenneth C

“…To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. A…”
Get full text

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study by Kumar, Shaji K, Prof, Berdeja, Jesus G, MD, Niesvizky, Ruben, Prof, Lonial, Sagar, Prof, Laubach, Jacob P, MD, Hamadani, Mehdi, MD, Stewart, A Keith, Prof, Hari, Parameswaran, Prof, Roy, Vivek, MD, Vescio, Robert, MD, Kaufman, Jonathan L, MD, Berg, Deborah, MSN, Liao, Eileen, PhD, Di Bacco, Alessandra, PhD, Estevam, Jose, BSc, Gupta, Neeraj, PhD, Hui, Ai-Min, MD, Rajkumar, Vincent, Prof, Richardson, Paul G, Prof

“…Summary Background The combination of bortezomib, lenalidomide, and dexamethasone is a highly effective therapy for newly diagnosed multiple myeloma. Ixazomib…”
Get full text

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies by Siegel, David, Martin, Thomas, Nooka, Ajay, Harvey, R Donald, Vij, Ravi, Niesvizky, Ruben, Badros, Ashraf Z, Jagannath, Sundar, McCulloch, Leanne, Rajangam, Kanya, Lonial, Sagar

“…Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent…”
Get full text

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma by Wang, Michael, Martin, Tom, Bensinger, William, Alsina, Melissa, Siegel, David S., Kavalerchik, Edward, Huang, Mei, Orlowski, Robert Z., Niesvizky, Ruben

“…We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple…”
Get full text

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma by Avet-Loiseau, Hervé, Fonseca, Rafael, Siegel, David, Dimopoulos, Meletios A., Špička, Ivan, Masszi, Tamás, Hájek, Roman, Rosiñol, Laura, Goranova-Marinova, Vesselina, Mihaylov, Georgi, Maisnar, Vladimír, Mateos, Maria-Victoria, Wang, Michael, Niesvizky, Ruben, Oriol, Albert, Jakubowiak, Andrzej, Minarik, Jiri, Palumbo, Antonio, Bensinger, William, Kukreti, Vishal, Ben-Yehuda, Dina, Stewart, A.Keith, Obreja, Mihaela, Moreau, Philippe

“…The presence of certain high-risk cytogenetic abnormalities, such as translocations (4;14) and (14;16) and deletion (17p), are known to have a negative impact…”
Get full text

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance by Kumar, Shaji K., Berdeja, Jesus G., Niesvizky, Ruben, Lonial, Sagar, Laubach, Jacob P., Hamadani, Mehdi, Stewart, A. Keith, Hari, Parameswaran, Roy, Vivek, Vescio, Robert, Kaufman, Jonathan L., Berg, Deborah, Liao, Eileen, Rajkumar, S. Vincent, Richardson, Paul G.

“…Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy…”
Get full text

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma by MARTIN, Peter, CHADBURN, Amy, MELNICK, Ari, KNOWLES, Daniel M, CHEN-KIANG, Selina, COLEMAN, Morton, LEONARD, John P, CHRISTOS, Paul, WEIL, Karen, FURMAN, Richard R, JIA RUAN, ELSTROM, Rebecca, NIESVIZKY, Ruben, ELY, Scott, DILIBERTO, Maurizio

“…Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though patients are commonly treated immediately at diagnosis. Because data on observation, or…”
Get full text

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group by DIMOPOULOS, Meletios A, TERPOS, Evangelos, COMENZO, Raymond L, SEZER, Orhan, PALUMBO, Antonio, HAROUSSEAU, Jean-Luc, RICHARDSON, Paul G, BARLOGIE, Bart, ANDERSON, Kenneth C, SONNEVELD, Pieter, TOSI, Patrizia, CAVO, Michele, CHANAN-KHAN, Asher, RAJKUMAR, S. Vincent, DURIE, Brian G. M, MIGUEL, Jésus San, LEUNG, Nelson, LUDWIG, Heinz, JAGANNATH, Sundar, NIESVIZKY, Ruben, GIRALT, Sergio, FERMAND, Jean-Paul, BLADE, Joan

“…Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal…”
Get full text

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups by Orlowski, Robert Z., Moreau, Philippe, Niesvizky, Ruben, Ludwig, Heinz, Oriol, Albert, Chng, Wee Joo, Goldschmidt, Hartmut, Yang, Zhao, Kimball, Amy S., Dimopoulos, Meletios

“…The phase III RandomizEd, OpeN Label, Phase 3 Study of Carfilzomib Plus DExamethAsone Vs Bortezomib Plus DexamethasOne in Patients With Relapsed Multiple…”
Get full text

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group by Raje, Noopur S, Anaissie, Elias, Kumar, Shaji K, Lonial, Sagar, Martin, Thomas, Gertz, Morie A, Krishnan, Amrita, Hari, Parameswaran, Ludwig, Heinz, O'Donnell, Elizabeth, Yee, Andrew, Kaufman, Jonathan L, Cohen, Adam D, Garderet, Laurent, Wechalekar, Ashutosh F, Terpos, Evangelos, Khatry, Navin, Niesvizky, Ruben, Yi, Qing, Joshua, Douglas E, Saikia, Tapan, Leung, Nelson, Engelhardt, Monika, Mothy, Mohamad, Branagan, Andrew, Chari, Ajai, Reiman, Anthony J, Lipe, Brea, Richter, Joshua, Rajkumar, S Vincent, Miguel, Jesús San, Anderson, Kenneth C, Stadtmauer, Edward A, Prabhala, Rao H, McCarthy, Phillip L, Munshi, Nikhil C

“…Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and…”
Get full text

IMWG consensus on maintenance therapy in multiple myeloma by Ludwig, Heinz, Durie, Brian G.M., McCarthy, Philip, Palumbo, Antonio, San Miguel, Jésus, Barlogie, Bart, Morgan, Gareth, Sonneveld, Pieter, Spencer, Andrew, Andersen, Kenneth C., Facon, Thierry, Stewart, Keith A., Einsele, Hermann, Mateos, Maria-Victoria, Wijermans, Pierre, Waage, Anders, Beksac, Meral, Richardson, Paul G., Hulin, Cyrille, Niesvizky, Ruben, Lokhorst, Henk, Landgren, Ola, Bergsagel, P. Leif, Orlowski, Robert, Hinke, Axel, Cavo, Michele, Attal, Michel

“…Maintaining results of successful induction therapy is an important goal in multiple myeloma. Here, members of the International Myeloma Working Group review…”
Get full text

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation by Cavo, Michele, Rajkumar, S. Vincent, Palumbo, Antonio, Moreau, Philippe, Orlowski, Robert, Bladé, Joan, Sezer, Orhan, Ludwig, Heinz, Dimopoulos, Meletios A., Attal, Michel, Sonneveld, Pieter, Boccadoro, Mario, Anderson, Kenneth C., Richardson, Paul G., Bensinger, William, Johnsen, Hans E., Kroeger, Nicolaus, Gahrton, Gösta, Bergsagel, P. Leif, Vesole, David H., Einsele, Hermann, Jagannath, Sundar, Niesvizky, Ruben, Durie, Brian G.M., San Miguel, Jesus, Lonial, Sagar

“…The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the…”
Get full text

Germline Lysine-Specific Demethylase 1 ( LSD1/KDM1A ) Mutations Confer Susceptibility to Multiple Myeloma by Wei, Xiaomu, Calvo-Vidal, M Nieves, Chen, Siwei, Wu, Gang, Revuelta, Maria V, Sun, Jian, Zhang, Jinghui, Walsh, Michael F, Nichols, Kim E, Joseph, Vijai, Snyder, Carrie, Vachon, Celine M, McKay, James D, Wang, Shu-Ping, Jayabalan, David S, Jacobs, Lauren M, Becirovic, Dina, Waller, Rosalie G, Artomov, Mykyta, Viale, Agnes, Patel, Jayeshkumar, Phillip, Jude, Chen-Kiang, Selina, Curtin, Karen, Salama, Mohamed, Atanackovic, Djordje, Niesvizky, Ruben, Landgren, Ola, Slager, Susan L, Godley, Lucy A, Churpek, Jane, Garber, Judy E, Anderson, Kenneth C, Daly, Mark J, Roeder, Robert G, Dumontet, Charles, Lynch, Henry T, Mullighan, Charles G, Camp, Nicola J, Offit, Kenneth, Klein, Robert J, Yu, Haiyuan, Cerchietti, Leandro, Lipkin, Steven M

“…Given the frequent and largely incurable occurrence of multiple myeloma, identification of germline genetic mutations that predispose cells to multiple myeloma…”
Get full text

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma by Niesvizky, Ruben, Ely, Scott, Mark, Tomer, Aggarwal, Sangeeta, Gabrilove, Janice L, Wright, John J., Chen‐Kiang, Selina, Sparano, Joseph A

“…BACKGROUND: Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDACs) induce DNA…”
Get full text

Deferring Autologous Stem Cell Transplantation for Consolidation of Minimal Residual Disease in Multiple Myeloma by Braunstein, Marc, MD, PhD, Niesvizky, Ruben, MD

“…The expanding armamentarium of novel agents used in combination to treat multiple myeloma (MM) can induce clinical responses in most newly diagnosed patients,…”
Get full text

High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma by Gomez-Arteaga, Alexandra, Mark, Tomer M., Guarneri, Danielle, Christos, Paul J., Gergis, Usama, Greenberg, June D., Hsu, Jingmei, Mayer, Sebastian A., Niesvizky, Ruben, Pearse, Roger N., Phillips, Adrienne A., Rossi, Adriana, Coleman, Morton, van Besien, Koen, Shore, Tsiporah B.

“…High-dose melphalan (MEL200) followed by autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma (MM). Bendamustine induces…”
Get full text

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma by Badros, Ashraf, Burger, Angelika M, Philip, Sunita, Niesvizky, Ruben, Kolla, Sarah S, Goloubeva, Olga, Harris, Carolynn, Zwiebel, James, Wright, John J, Espinoza-Delgado, Igor, Baer, Maria R, Holleran, Julianne L, Egorin, Merrill J, Grant, Steven

“…Purpose: Vorinostat, a histone deacetylase inhibitor, enhances cell death by the proteasome inhibitor bortezomib in vitro . We sought to test the combination…”
Get full text

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma by NIESVIZKY, Ruben, MARTIN, Thomas G, BENSINGER, William I, ALSINA, Melissa, SIEGEL, David S, KUNKEL, Lori A, WONG, Alvin F, LEE, Susan, ORLOWSKI, Robert Z, WANG, Michael

“…Carfilzomib, a selective proteasome inhibitor, has shown safety and efficacy in relapsed and/or refractory multiple myeloma. This phase I study in patients…”
Get full text

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma by HUSSEIN, Mohamad, BERENSON, James R, NIESVIZKY, Ruben, MUNSHI, Nikhil, MATOUS, Jeffrey, SOBECKS, Ronald, HARROP, Kate, DRACHMAN, Jonathan G, WHITING, Nancy

“…This first-in-human, phase I study evaluated the safety, maximum-tolerated dose, pharmacokinetics, and antitumor activity of dacetuzumab in 44 patients with…”
Get full text

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance by Mejia Saldarriaga, Mateo, Darwiche, Walaa, Jayabalan, David, Monge, Jorge, Rosenbaum, Cara, Pearse, Roger N, Niesvizky, Ruben, Bustoros, Mark

“…Recent insight in the genomic landscape of newly diagnosed multiple myeloma (NDMM) and its precursor conditions, monoclonal gammopathy of uncertain…”
Get full text